<SEC-DOCUMENT>0000313143-17-000037.txt : 20171018
<SEC-HEADER>0000313143-17-000037.hdr.sgml : 20171018
<ACCEPTANCE-DATETIME>20171018161155
ACCESSION NUMBER:		0000313143-17-000037
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20171017
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171018
DATE AS OF CHANGE:		20171018

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HAEMONETICS CORP
		CENTRAL INDEX KEY:			0000313143
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				042882273
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			0328

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14041
		FILM NUMBER:		171142733

	BUSINESS ADDRESS:	
		STREET 1:		400 WOOD RD
		CITY:			BRAINTREE
		STATE:			MA
		ZIP:			02184
		BUSINESS PHONE:		7818487100

	MAIL ADDRESS:	
		STREET 1:		400 WOOD ROAD
		CITY:			BRAINTREE
		STATE:			MA
		ZIP:			02184
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>abernathy8-k.htm
<DESCRIPTION>8-KABERNATHY
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s20784575d5a843f3bf2b80d341022bc7"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM&#160;8-K</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 OR 15(d)&#160;of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (Date of earliest event reported) &#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;October 17, 2017</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">HAEMONETICS CORPORATION</font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:624px;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:198px;"></td><td style="width:13px;"></td><td style="width:198px;"></td><td style="width:13px;"></td><td style="width:200px;"></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Massachusetts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1-14041</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">04-2882273</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;padding-left:4px;text-indent:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction</font></div><div style="padding-bottom:2px;text-align:center;padding-left:4px;text-indent:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;padding-left:4px;text-indent:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission</font></div><div style="padding-bottom:2px;text-align:center;padding-left:4px;text-indent:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">File Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;padding-left:4px;text-indent:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(I.R.S. Employer</font></div><div style="padding-bottom:2px;text-align:center;padding-left:4px;text-indent:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:624px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:305px;"></td><td style="width:12px;"></td><td style="width:306px;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">400 Wood Road, Braintree MA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">02184</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">Registrant&#8217;s telephone number, including area code&#160; </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">781-848-7100</font></div><div style="line-height:174%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former name or former address, if changed since last report.)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:643px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:24px;"></td><td style="width:618px;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:center;padding-left:28px;text-indent:-2px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:92.7734375%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:0%;"></td><td style="width:19%;"></td><td style="width:20%;"></td><td style="width:16%;"></td><td style="width:25%;"></td><td style="width:20%;"></td></tr><tr><td><font>&#160;</font></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="5" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:9px;text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;color:#231f20;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></div></td></tr><tr><td><font>&#160;</font></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Emerging growth company</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">o</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="5" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the </font></div><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br></font></div></td></tr><tr><td><font>&#160;</font></td></tr><tr><td><font>&#160;</font></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Exchange Act.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:Wingdings;font-size:9pt;">o</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:28px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:28px;text-indent:144px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:11pt;padding-left:0px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Item 5.02</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">DEPARTURE OF DIRECTORS OR CERTAI OFFICERS; ELECTION OF DIRETORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:1px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">On October 17, 2017, the Board of Directors of Haemonetics Corporation (the &#8220;Company&#8221;) elected Robert E. Abernathy to serve as a Class III Director for a term expiring at the 2020 Annual Meeting of Shareholders and appointed Mr. Abernathy to serve as a member of the Compensation Committee of the Board of Directors.  Mr. Abernathy was formerly Chairman of the Board of Directors and Chief Executive Officer of Halyard Health, Inc.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:1px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">As a non-employee director of the Company, Mr. Abernathy will receive compensation as described in the &#8220;Directors&#8217; Compensation&#8221; section of the Company&#8217;s 2017 Proxy Statement.  In connection with his election, Mr. Abernathy received a grant of 2,909 Restricted Stock Units representing a pro rata annual equity grant based on the number of days to be served from Mr. Abernathy&#8217;s election through the first anniversary of the 2017 Annual Meeting of Shareholders, on which date the Restricted Stock Unit award vests in full.  </font></div><div style="line-height:120%;text-align:justify;text-indent:32px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">A copy of the Company&#8217;s press release announcing the election of Mr. Abernathy is filed with this Current Report on Form 8-K as Exhibit 99.1.</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:1px;text-indent:0px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s6f3b1ce7210442c1b733ff57535cf7fc"></a></div><div style="line-height:120%;padding-bottom:22px;text-align:left;padding-left:1px;text-indent:0px;-sec-extract:summary;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Item 9.01               FINANCIAL STATEMENTS AND EXHIBITS</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;">Exhibits</font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:11%;"></td><td style="width:3%;"></td><td style="width:86%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit&#160;</font></div><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">99.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:11pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="a10182017robertabernathypr.htm"><font style="font-family:inherit;font-size:11pt;">Press Release dated October 18, 2017</font></a></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;text-align:center;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:6px;text-align:center;padding-left:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;text-align:center;padding-left:4px;text-indent:-2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-bottom:6px;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:6px;text-align:left;padding-left:1px;text-indent:0px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;text-align:left;padding-left:4px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.4140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">HAEMONETICS CORPORATION</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date:&#160;&#160;October 18, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Christopher Simon</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Christopher Simon, President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:4px;text-indent:-2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:4px;text-indent:-2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:0px;text-align:left;padding-left:4px;text-indent:-2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a10182017robertabernathypr.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sE8BE9CBD835B0EDE99D02FCE8EA6253B"></a></div><div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:20pt;"><img src="a10182017robertaberna_image1.gif" alt="a10182017robertaberna_image1.gif" style="height:52px;width:216px;"><font style="font-family:inherit;font-size:7.5pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><font style="font-family:inherit;font-size:20pt;color:#c60c30;font-weight:bold;">News Release</font></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:46%;"></td><td style="width:4%;"></td><td style="width:9%;"></td><td style="width:41%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:21px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">FOR RELEASE</font><font style="font-family:Arial;font-size:12pt;">:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">CONTACT:</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Date   October 18, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Gerry Gould, VP-Investor Relations</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Time   8:00 am Eastern</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">(781) 356-9402</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#005cc7;text-decoration:underline;">gerry.gould@haemonetics.com </font></div><div style="font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:336px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:12pt;color:#ff0000;font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:138%;text-align:center;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;font-weight:bold;">Robert E. Abernathy Joins Haemonetics Board of Directors</font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Braintree, MA, October 18, 2017 </font><font style="font-family:Arial;font-size:12pt;">&#8211; Haemonetics Corporation (NYSE:HAE) announced the election of Robert E. Abernathy, a seasoned healthcare executive, to its Board of Directors. Mr. Abernathy has led major medical businesses in North America and Europe with Halyard Health, Inc. </font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Richard J. Meelia, Chairman of Haemonetics&#8217; Board of Directors commented: &#8220;Robert Abernathy brings us extensive experience in the healthcare industry and in international operations, with in-depth knowledge of the needs of healthcare providers and patients. We welcome him and look forward to his contribution to our Company&#8217;s success.&#8221;</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Mr. Abernathy served as Chairman of the Board of Directors and Chief Executive Officer of Halyard Health, Inc., a Kimberly-Clark Corporation spinoff medical technology company specializing in important patient health care needs. Over 35 previous years, his positions of increasing responsibility included President of Kimberly-Clark&#8217;s Global Health Care business; Group President, Developing &amp; Emerging Markets; Managing Director, Kimberly-Clark Australia and President, North Atlantic Consumer Products.</font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Mr. Abernathy previously served on the Board of Directors of The Advanced Medical Technology Association (AdvaMed). He earned a Bachelor of Science degree in chemistry from the University of Alabama and a Master&#8217;s of Science degree in paper chemistry from the Institute of Paper Chemistry at Lawrence University.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">ABOUT HAEMONETICS</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:150%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;background-color:#ffffff;">Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions for our customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at </font><font style="font-family:Arial;font-size:12pt;background-color:#ffffff;color:#005cc7;text-decoration:underline;">http://www.haemonetics.com</font><font style="font-family:Arial;font-size:12pt;background-color:#ffffff;">. &#160;&#160;&#160;&#160;</font></div><div><br></div><div><div style="line-height:150%;text-align:right;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;">1</font></div><div style="line-height:150%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>a10182017robertaberna_image1.gif
<TEXT>
begin 644 a10182017robertaberna_image1.gif
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M\7G'W&SRT=:R-QQ]DQ-N@5G=E39@B//IG*5\.HQXV&MG!23 )6:+RQ[[^,=
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M^()\$(A %SQ!"KB&? 1=R(4("3H.4BRP 0U0;04\"Y5S,,,2):C !<A0BG'
M0QRFL,0%1(Z!DJ_@!C0X.@N4WKR36_0&S8, "5) @QLLON0:J( -(#_YI5=@
M:^$PA2=8T#P*E-P"9TCYSOF'B2MLH $"N( /SG &'[!@!5W Q/K&\![DX:,<
M:KB VC'AB4KXX/%K0$,)T'$O='#"$FA@82XP831]O*E80R  _R9H=J<\::P^
MX6B<GC@ X_F8MZL,,%[BG (/3_! '-0$7"M>$(LH( &/3 %!'C,"Y2!3A_5?
M^Q(+#;  2O$!O* WOE(%<7(WUK,W+B %#'  .+$ #& %")@6-M )SC(+FT%9
M&[8OF74&9$!/*7 +*\)1L#4N9H(.-0!B,<$WQ3(H*\9>SN "WL0 ;A!(#A$/
MN% !"I9='$ WJU O6 $/:! !1H4/X< )2X4)/H )N!,BPP Q<A)=V$5==8,3
MUQ4W6( %L- I1R%@U(<H%0 V+G,BZ' #,_-8-O,]GJ !]T59(^!2#[$+-K +
M!!(!J0(%"%@.!( Q.J$!I-!:^= +C?^#! ?  !KP#)9E LX0#_@0"VTX!)^4
M "  B&D!6J)5$W>C-A<"#1$ "SR6.!U%3+(U'^C"%KX4(LZ@?A+F .2P']#P
M73A!602P 6G0#/H3(MBE&OCP,*'& %R0"[Q0"LVP#,S #)X@@6$TAGJ!#V:P
M @4##YB A^'5@0Z6/'"2:E/ ?&G  7,5CC*!5RXE8IB$!%T@/SY0"1-C6$J!
M6#&1"6>#7XXE']" 3QA#60A%BS30#&V"#T,%7N'E %CH I[ (F;#B8."!9[0
M"59P-Z]@8E A-ZE" *\H'WSC-^] 2N_0!G23%%3 A_J!#^;@"?AT.;QU!)%H
M X6F&OGP)A'_(U!VP@5Q0DS =36H4'D1,)1IUX8+\'\(@ %KH#<K<Q,K)4VI
M80XI4"_?, KT! ^L8 ,JB0[?%48=:$SVR !%TRI?D('$I)/P@0^88%:?Q  ^
MT"M9XPQ/TTYX<E]&<  <4&&M0H(10R<A @@/^12BP QQ,UQ*@3<Z$G A>5L#
M90XW@$D,X GJJ!KP  B?0#,#0@Q.<#'AUP,:R3:0N8.0(DR>803%I$KZ$ ^Q
M4#TC67'[4 XA0"R4]0%9!Q7.I!-&0 17H%Q7 P_F@ D;\ 0V>"_OL J:HA?0
MT(8=$%H",P"\- 0%  7#\&_X8 PPP  *T('M1U#D($S3,@+#H"/X_[ +)0"(
MK@DXN2*)>DE0KP)^$J-*"O(.Y) &1JB23Z$/,-A0>--:)^(,H;ES[X )!G@W
MJ4 A_W8FSC #8T48[Z &=X,L%<)<Q(DGG:6.Z# .YE E&JJAYL F6I*A&VHE
M5C(.MC,.&]JATO4.XX"A(5HEI;.B(-JB''JB(_D0*WJBAB<P*Z*B)BJC'>I@
MG5,.SL +;><)N<!#:85=*AJCY;"B)H8/XK Q,'.C,MJB,;IS/W(./=JB*[IS
MZX"A3*JA*ZHW4B*DOB ++,0+2"J 49HBYC"DI> )I<!#DRE(KG807K9$N<85
M>?9N?FH2EF1'F(9O]V84IT9HLW6G")&G8/^VI[JV;GKVI^]&;&!$J( V:,T&
M'XJ*IW2F:';FJ!71IY(JJ92Z:9;*9IBJ9?&QJ7[1J7H*JA@AJJ/JIZ5ZJLB6
MJC7Y%*Q:%:[:J+#Z1) ZJW]:J[8::+B:J+LZ$(RZ:+\Z![(JK,)&K,6*JIN6
M9;EJI\FZK)\*J\\*K9,FK=-J9<>Z9<E:"($Q"5@A#WZPK:#Z%<A1#\ &:9'F
MK6:&1>#R&8-Z1VVQK_S:K_[ZKP ;L (+L'9A%$"P *LV'\D::[)&:W6&:\TZ
M!W3 !]8 220QK_3Z9%%6+ =;FE06KINT;VR!J.2:K0[KJ1#;K(WT2+TV"+^6
ML7QFKWF2,8("2KC_:2S+9F^XF;-+<[,\B[,]J;,XR[,^&[1$F[,-Q10*FZP$
M44CIFDCA-@=Q(+48,;566[54:[7N"A*1T;4P6V;Q!CAGL(G)!K*<9!0TVQ:&
MJFKE<)X/H0B, +=P&[=T*[=U:[=XRPAZNPB+8 B'D C>$!/S, UV  >&>P>(
MF[B*N[B,V[AU4 =[< U1U&Y?RV=AFQED  $GM+F<V[F>^[F@&[JB.[JDR[D1
MD(NWQ%RJ^Q3WH _S\+KS<"^R.[NT6[NVZ[JQ.W$^MB)NJ[OT 2(=Y[O".[S$
M6[S&>[S(F[S*N[S,*[S!V[S0&[W2.[W4ZTH;-Q_/2[W7"V39BW#=RTH=__>]
M]0$D";>*!B>^/K:]/_)PZOL?IB *6(4)F8 )\GM5G" *\/ .\!N_]$N_EG"_
MXN GGA# \Q$.^UL)\TN_GL )FY!56;7 I5"/H@"_F]"_F6 )G@!8^Q"\B=>_
MG;# G! *-]<J'%0)P=,%*&P&9U )T,.F6-4)'JPY[W&]^2 .H'!]G=# G" .
M\, ,% S#_?N_6/6_E= ),&P)#<->I<!\]IM5%HP)G5 )0LP)'QPJS! *0]R_
MF"#$HH"E[%4.S=<%6$!T77 &G& *% (/Y6 )H@(SI1 \8[Q[FD,@@6!1=5<*
M>%QSAX(.F  V#' #1J5*Q]B5AUF;],%1$P#(O_\[GH-#65;0"^(@#N$0#LY@
MD=%R!>1P2@^!#CSC+WYEGZV2"VV8*A] 6*J!#FLP A1  "/@">80#W"H"Q<I
M8&<PC,HR##FU&0F  6FPAO&#"1?$FYM<E@5$65W@#)-,R:60R@30 !6U+X#2
M &E0"I/<#'5YF*TPR<[@"3:PRL/@;SH#S$JS4E:0R919"C< 3PRP 6I .C#R
MIIBP>$RP4^#<3EW0/+%P)?'@(K%@ QE@<J$BA9S "SC0"5<(#6JP+[\ F5ZX
MD3R#,<7TNP%J.2U5'^9U%_)G8<%T _C')9@" VP0*$K!!752<=   K/P =Z4
M /B8.&#@ *38RZZ%"6S_Q0#QB%W#T#@)@ 0_< 0,  *X $'FL (5N)=^?((Q
M$3Z\( '/S%XSH)4JTXIW0RX$%0L70&"T-;,+()KX$%/_EP 5L)T:K<H*M@_0
M4 5W4POK54_/, (0X"CX$ Q*I0-7< .FX@,Q@9,--7YV@@7C?'[S$3@U813K
M4J>)LBA#D-$Z(P9 $@Z T-'UU HK0 X.&EZ[(M0TX :),H@?: ZHTE#2%&)=
M4&^$!A7"L *Q<)&06"SQURV)8P/-@ETD*"UI4RVF4 K[4@IE,'<$(RJO-8$R
MV)N H'(WR%9VLX/F\ 71HA0@H,'QH3,W8 ;O@2L4,"UA#4'\4P+*]0X8W O<
M_X$+9("Z-PDGGS$G.U=^G C8\0$/LE !38!)!( *&IDHQ<(HV^@)4PE6F8(.
MYC W]W4WI_""/D &WR.()-;2,J%^.M$ #W0KL; $I*6&EE4"P/ .RC ""-"3
M0\ !FD!/[X#:([C<I7@H\' #JG@?OVT$XO*1\1&+ZK)BZ%"6Z*04O:"1R(,.
MHA 3G@ OW]@ 70 -W_,4/'PIY6 *SC!W[*772N$&%+(@!%(.6G!?7O63%N8,
M%P +PN5-X;>>IZPHQJ(%AH(.04E78,4*-\,_U24OL9T99Z #W0(/!GZ/"+C0
MO?2)C&@,CV@W''#B/Q*7_L:-&* TJ28#0Z0S*\"<K?]B-J0X)]]3,0) "QK)
MBN'BD3RVF,=]E;XP6EWU 51>'VH!3WI"8C^=!L.0I!+R)J=1 1)0 A+0ZB7
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#(  [

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
